Werewolf <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Faces Nasdaq Noncompliance After Audit Committee Member's Passing; Plans to Regain Compliance
**Werewolf Therapeutics Announces Noncompliance with Nasdaq Listing Rule Following Board Member's Passing** Werewolf Therapeutics Inc. disclosed that it is no longer in compliance with Nasdaq Listing Rule 5605(c)(2) after the passing of Dr. Alon Lazarus, a member of its Board of Directors, on September 30, 2025. Dr. Lazarus's death reduced the number of independent directors on the company's Audit Committee to two, below the required minimum of three. The company notified Nasdaq of the noncompliance on October 2, 2025, and is entitled to a cure period that extends until its next annual stockholder meeting or September 30, 2026, whichever comes first. Werewolf Therapeutics stated it intends to restore compliance by appointing a new independent director as soon as possible.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Werewolf Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-231953), on October 06, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。